Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma (Q33376711)

26 July 2017

title

Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma (English)

1 reference

26 July 2017

0 references

1 reference

Shuji Ozaki

1

1 reference

26 July 2017

Osamu Tanaka

2

1 reference

26 July 2017

Shiro Fujii

3

1 reference

26 July 2017

Yuri Shigekiyo

4

1 reference

26 July 2017

Hirokazu Miki

5

1 reference

26 July 2017

Masahito Choraku

6

1 reference

26 July 2017

Kumiko Kagawa

7

1 reference

26 July 2017

Jin Asano

8

1 reference

26 July 2017

Kyoko Takeuchi

9

1 reference

26 July 2017

Ken-ichi Kitazoe

10

1 reference

26 July 2017

Toshihiro Hashimoto

11

1 reference

26 July 2017

Masahiro Abe

12

1 reference

26 July 2017

Toshio Matsumoto

13

1 reference

26 July 2017

publication date

1 August 2007

1 reference

International Journal of Hematology

26 July 2017

published in

1 reference

26 July 2017

volume

86

1 reference

26 July 2017

issue

2

1 reference

26 July 2017

page(s)

180-185

1 reference

High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation

26 July 2017

cites work

1 reference

12 December 2020

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

1 reference

12 December 2020

International staging system for multiple myeloma

1 reference

12 December 2020

Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

1 reference

12 December 2020

Dexamethasone reduces the risk of bortezomib-induced pulmonary complications in Japanese myeloma patients

1 reference

12 December 2020

Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "lung injury by bortezomib" joint committee of the Japanese society of hematology and the Japanese society of clin

1 reference

12 December 2020

Molecular mechanisms of novel therapeutic approaches for multiple myeloma

1 reference

12 December 2020

1 reference

12 December 2020

Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma

1 reference

12 December 2020

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

1 reference

12 December 2020

Severe pulmonary complication after bortezomib treatment for multiple myeloma

1 reference

12 December 2020

Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

1 reference

12 December 2020

The proteasome: a suitable antineoplastic target

1 reference

12 December 2020

Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2.

1 reference

12 December 2020

Treatment of multiple myeloma

1 reference

12 December 2020

PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma

1 reference

12 December 2020

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

1 reference

12 December 2020

Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion

1 reference

12 December 2020

Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-?B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma

1 reference

12 December 2020

Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro

1 reference

12 December 2020

Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model

1 reference

12 December 2020

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

12 December 2020

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

1 reference

12 December 2020

Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.

1 reference

12 December 2020

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

1 reference

12 December 2020

Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment

1 reference

12 December 2020

Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma

1 reference

12 December 2020

International uniform response criteria for multiple myeloma.

1 reference

12 December 2020

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

1 reference

12 December 2020

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

12 December 2020

Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.

1 reference

12 December 2020

Pathogenesis of myeloma bone disease

1 reference

12 December 2020

The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions

1 reference

12 December 2020

Identifiers

DOI

10.1532/IJH97.07030

1 reference

Dimensions Publication ID

26 July 2017

1046239132

0 references

Fatcat ID

release_t3arnc6unvcoddr7ri2trtuwwa

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/t3arnc6unvcoddr7ri2trtuwwa

24 November 2022

mapped directly with Wikidata item

1 reference